A real example: what you get
3 new papers close to the project “Antibiotic Exposure and the Response to Anti-PD-1 Therapy in Advanced Melanoma: A Retrospective Cohort Study”, found in the announcements of its first days
- How close it is on each facet: question, method, data, results
- What it shares with your project and what stays your own
- What to do: cite it, set your project apart, contact the authors, hurry
- The prior art of the last three years, and the new papers of the teams you name
Partial overlap
Both studies examine factors associated with outcomes of PD-1 blockade in melanoma using observational patient data. This paper evaluates tumour transcriptional states and disease control rather than antibiotic exposure, objective response and overall survival.
Glycolysis and interferon transcription in melanoma immunotherapy
What stays your own
The project's contribution remains its assessment of systemic antibiotic exposure around treatment initiation in a three-hospital cohort, with adjustment for clinical prognostic factors. Distinguish this clinical exposure analysis from transcriptomic biomarker studies, and avoid presenting either study as direct evidence that antibiotics impair treatment through the gut microbiome.
The email you would have received · 3 new papers are close to your projects
The first results
-
Glycolysis and interferon transcription in melanoma immunotherapy
Partial overlap
Both studies examine factors associated with outcomes of PD-1 blockade in melanoma using observational patient data. This paper evaluates tumour transcriptional states and disease control rather than antibiotic exposure, objective response and overall survival.
-
Antibiotics drive immunometabolic rewiring of human immune responses
Partial overlap
The paper shows that certain antibiotics can impair human T-cell activation and expansion, providing a potential biological explanation for an association between antibiotic exposure and poorer anti-PD-1 outcomes. It also suggests that antibiotic effects on immunity need not be mediated …
-
Comprehensive real-world utilization, treatment trajectories, and outcomes of immune checkpoint inhibitors across cancer types: the multicenter FAIR-ICI cohort
Partial overlap
Both studies use multicenter retrospective clinical cohorts to evaluate survival after immune checkpoint inhibitor treatment, including melanoma, with adjustment for prognostic characteristics. FAIR-ICI specifically identifies performance status as an important survival predictor, supporting its consideration in the project's analysis.
See a complete example, explained step by step →
